Vemurafenib is a specific mutant BRAF inhibitor; consistently, in the in vitro models used here, the SK-MEL-28 cell line and primary melanoma cells (both harboring BRAFV600) were sensitive to this drug, reaching an IC50 lower than 1 μM. Here, BRAF is linked to melanoma.